[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,306
Citations 0
Correction
November 2014

Missing Conflict of Interest Disclosure

JAMA Intern Med. 2014;174(11):1875. doi:10.1001/jamainternmed.2014.5554

In the Original Investigation titled “Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer: Results From the Randomized Clinical Trials of Alendronate and Zoledronic Acid” published in the October 2014 issue of JAMA Internal Medicine (2014;174[10]:1551-1558. doi:10.1001/jamainternmed.2014.3634), there was an error in the Conflict of Interest Disclosures.

The correct version reads as follows: “Dr Ensrud serves as a consultant on a data monitoring committee for Merck Sharp & Dohme. Dr Black has received grant support from Novartis and Merck and consulting, lecture, or advisory board fees from Lilly, Novartis, Amgen, Radius, and Merck. No other disclosures are reported.” This article was corrected online.

×